Rachel Roberts
Project Manager, Multi-Stage Malaria Vaccine Consortium (MMVC)
Recent publications
-
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials
Journal article
Venkatraman N. et al, (2025), The Lancet Microbe, 100868 - 100868
-
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.
Journal article
Venkatraman N. et al, (2025), The Lancet. Microbe
-
Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children.
Journal article
Natama HM. et al, (2024), The Lancet. Infectious diseases
-
Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial
Journal article
Silk SE. et al, (2024), The Lancet Infectious Diseases, 24, 1105 - 1117
-
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial
Journal article
Datoo MS. et al, (2024), The Lancet, 403, 533 - 544